Abbott Laboratories
ABT
$87.77
-$0.61-0.69%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.13B | 44.33B | 43.84B | 43.11B | 42.34B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.13B | 44.33B | 43.84B | 43.11B | 42.34B |
| Cost of Revenue | 19.73B | 19.31B | 19.28B | 18.90B | 18.65B |
| Gross Profit | 25.40B | 25.02B | 24.57B | 24.21B | 23.70B |
| SG&A Expenses | 12.36B | 11.69B | 11.49B | 11.34B | 11.20B |
| Depreciation & Amortization | 1.68B | 1.68B | 1.73B | 1.78B | 1.83B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.75B | 35.61B | 35.42B | 34.90B | 34.53B |
| Operating Income | 8.38B | 8.72B | 8.42B | 8.21B | 7.82B |
| Income Before Tax | 8.14B | 8.47B | 8.14B | 7.90B | 7.36B |
| Income Tax Expenses | 1.86B | 1.94B | -5.84B | -6.08B | -6.15B |
| Earnings from Continuing Operations | 6.28K | 6.52K | 13.98K | 13.98K | 13.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.28B | 6.52B | 13.98B | 13.98B | 13.50B |
| EBIT | 8.38B | 8.72B | 8.42B | 8.21B | 7.82B |
| EBITDA | 11.55B | 11.84B | 11.55B | 11.35B | 10.99B |
| EPS Basic | 3.59 | 3.73 | 8.01 | 8.01 | 7.74 |
| Normalized Basic EPS | 2.94 | 3.06 | 2.96 | 2.88 | 2.74 |
| EPS Diluted | 3.56 | 3.71 | 7.97 | 7.97 | 7.70 |
| Normalized Diluted EPS | 2.94 | 3.05 | 2.96 | 2.87 | 2.73 |
| Average Basic Shares Outstanding | 6.98B | 6.97B | 6.97B | 6.97B | 6.97B |
| Average Diluted Shares Outstanding | 6.99B | 6.99B | 6.99B | 6.99B | 6.99B |
| Dividend Per Share | 2.44 | 2.40 | 2.36 | 2.32 | 2.28 |
| Payout Ratio | 66.73% | 63.09% | 28.93% | 28.42% | 28.92% |